OnDemand WTP Pricing Research

Drugmaker Group Boosts Lobbying as Push to Lower Prices Stalls | Bloomberg

The drug industry’s primary trade group increased its spending on lobbying during the second quarter, as President Donald Trump’s promised efforts to lower the prices of prescription drugs stalled.

The Pharmaceutical Research and Manufacturers of America, which represents leading drugmakers, reported spending $6.2 million in the quarter that ended June 30, a 12% increase from $5.5 million in the same period last year, according to a disclosure filed with Congress by Monday’s deadline. The group reported lobbying on several pieces of legislation that dealt with drug pricing.

Separately, Johnson & Johnson reported lobbying spending of $2.2 million in the second quarter, compared with $870,000 in the same period in 2018. Eli Lilly & Co. showed spending of $2.3 million in the quarter, up from $1.5 million last year. Both companies reported lobbying on drug-pricing legislation in their disclosures to Congress.

Read complete article here:

Drugmaker Group Boosts Lobbying as Push to Lower Prices Stalls – Bloomberg.

Post a Comment

WP-SpamFree by Pole Position Marketing